Drug profile

The FDA adverse-event record for Kidney Supplement

32 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Kidney Supplement. Species, reactions, and outcomes follow.

#1400 of 2,679
by report volume (all drugs)
32
adverse-event reports
18.8%
death-coded share
Cat
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Kidney Supplement ranks #1387 of 2679 by total reports (32). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1387
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Kidney Supplement has 32 reports now versus 31 in that prior snapshot: 1 more (3.2%).

Report change
+1
Death-coded reports
+0
Death-coded share
−0.6 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Kidney Supplement changes

Signature read: Kidney Supplement's 18.8% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
32
Total Reports
6
Deaths Reported
18.8%
Death-coded share of reports

Active Ingredients

Kidney Supplement

Administration Routes

UnknownOral

Species Affected

Cat 17
Dog 15

Most Affected Breeds

Domestic Shorthair 11
Dog (unknown) 2
Cat (unknown) 2
Terrier - West Highland White 1
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 1
Terrier - Fox (unspecified) 1
Beagle 1
Terrier - Jack Russell 1
Poodle (unspecified) 1
Retriever - Labrador 1

Most Reported Reactions

Vomiting 6
Elevated alanine aminotransferase (ALT) 5
Death by euthanasia 4
Behavioural disorder NOS 4
Lack of efficacy - NOS 4
Lethargy (see also Central nervous system depression in Neurological) 4
Weight loss 4
Lethargy (see also Central nervous system depression in 'Neurological') 3
Not eating 3
Diarrhoea 3
Elevated blood urea nitrogen (BUN) 3
Elevated renal parameters 2

Outcome Breakdown

Outcome Unknown
12 (37.5%)
Ongoing
8 (25.0%)
Recovered/Normal
6 (18.8%)
Euthanized
4 (12.5%)
Died
2 (6.3%)

Kidney Supplement: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Kidney Supplement (#1400 of 2,679 by report volume); death-coded 18.8%. PlainBreed drug row · death-coded share stamp 18.8% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →